MarginsXMarginsX
Home › Data Desk › Evommune Inc. revenue down 100.0% in the quarter to Sep 30, 2026

MarginsX Data Desk · Quarterly results · Licensing and milestone payments · Early-stage clinical trials · Private placement (PIPE)

Evommune Inc. revenue down 100.0% in the quarter to Sep 30, 2026

The 10-Q that Evommune Inc. (EVMN) filed on Nov 12, 2026 covers the quarter ended Sep 30, 2026. (SEC XBRL company facts, 10-Q, Nov 12, 2026)

By the MarginsX Data Desk, automated. Published November 14, 2026. Data as of November 12, 2026.

Bar chart of Evommune Inc.'s quarterly revenue from Dec 31, 2024 to Sep 30, 2026, the latest quarter highlighted.

Revenue and margins

Revenue was $0, down 100.0% from $10.0M in the same period a year earlier, which ended Sep 30, 2025. (SEC XBRL company facts, 10-Q, Nov 12, 2026)

The net loss was $30.9M. (SEC XBRL company facts, 10-Q, Nov 12, 2026)

Balance sheet

Cash was $47.6M at Sep 30, 2026, against $60.0M at Jun 30, 2026. (SEC XBRL company facts, 10-Q, Nov 12, 2026)

Shares outstanding were 41.3 million, against 36.3 million at Jun 30, 2026, a rise of 13.9%. (SEC XBRL company facts, 10-Q, Nov 12, 2026)

The stock

The Nasdaq screener puts its market value at $331.6M. (Nasdaq stock screener, Nov 13, 2026)

Follow it up

The company's page on MarginsX, with its filings, health check and ownership. (capital.sophiaxt.com/stocks/EVMN)

The filing on SEC EDGAR. (sec.gov)

The filing in the MarginsX reader. (MarginsX reader)

Automated from SEC filings and market data by the MarginsX Data Desk, written by template with no AI. For information only. Not investment advice.

Facts behind this article

FactValueSourceAs of
NameEvommune Inc.Source2026-11-13
Revenue change-1 %Source2026-11-12
Revenue0 USDSource2026-11-12
Revenue a year earlier10,000,000 USDSource2026-11-12
Period endSep 30, 2026Source2026-11-12
Form10-QSource2026-11-12
WhoEvommune Inc. (EVMN)Source2026-11-13
SymbolEVMNSource2026-11-13
FiledNov 12, 2026Source2026-11-12
A year earlier endSep 30, 2025Source2026-11-12
Net loss30,877,000 USDSource2026-11-12
Net income-30,877,000 USDSource2026-11-12
Cash47,570,000 USDSource2026-11-12
Cash prior60,034,000 USDSource2026-08-06
Prior endJun 30, 2026Source2026-08-06
Shares41,349,860 sharesSource2026-11-12
Shares prior36,292,113 sharesSource2026-08-06
Dilution0.139 %Source2026-11-12
Cap331,625,877 USDSource2026-11-13

Sources

Automated from SEC filings and market data. No AI. For information only. Not investment advice.

Discuss in MarginsX More from the Data Desk

More on MarginsX

Companies in this article

Topics

Related Data Desk stories

Every Data Desk article: /desk · RSS